On May, 9 The EPS for Collegium Pharmaceutical, Inc. (COLL) Expected At $-0.62

April 17, 2018 - By Richard Doty

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

On May, 9. Investors expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to reveal its quarterly earnings, according to Zacks. Analysts have anticipation on stock’s earnings per share of $-0.62. That’s up 21.52 % from last year’s $-0.79 earnings per share. 14.81 % negative EPS growth is what analysts predict. $-0.54 earnings per share was announced for last [previous quarter]. The stock decreased 0.34% or $0.08 during the last trading session, reaching $23.2.Collegium Pharmaceutical, Inc. has volume of 381,792 shares. Since April 17, 2017 COLL has risen 133.98% and is uptrending. COLL outperformed by 122.43% the S&P 500.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 3 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 8 are the (NASDAQ:COLL)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. In Tuesday, January 23 report Piper Jaffray maintained the stock with “Buy” rating. On Thursday, December 14 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. On Sunday, February 11 the company was maintained by Jefferies. In Wednesday, November 29 report Piper Jaffray maintained the stock with “Buy” rating. On Wednesday, October 18 the firm has “Buy” rating given by Jefferies. On Monday, February 12 the company was maintained by Piper Jaffray. On Thursday, December 7 the rating was maintained by Piper Jaffray with “Buy”. On Monday, November 6 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Janney Capital.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $766.24 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.